Final assessment

Where OpenEvidence is weaker than MontMedical.

The strongest supported weakness in these examples is overinterpreting a useful finding. Both tools often identify the same leading disease. The difference is whether the explanation preserves the gap between the observed result and the mechanism it claims.

  1. Localising an abnormality too precisely. In the prothrombin case, the abnormality follows a patient-derived preparation. OpenEvidence assigns it to the molecule itself and treats the long peptide-cleavage tail as the characteristic inhibition defect. MontMedical separates preparation-level transfer, substrate cleavage and direct inhibition kinetics.
  2. Inferring the causal gene from a pathway response. In hereditary xerocytosis, both answers identify the correct disease group. OpenEvidence's later blocker discussion moves towards KCNN4-associated disease; MontMedical explains why a PIEZO1 defect can activate the same downstream Gardos channel.
  3. Overstating specificity or exclusion. The platelet case calls an aggregation clue specific and recommends removing a historical diagnosis. The CANOMAD answer treats Bing–Neel syndrome as effectively excluded. MontMedical more precisely distinguishes a strong leading interpretation from a categorical exclusion.

Where OpenEvidence is stronger

OpenEvidence gives the more connected physiological explanation in LPI and the more useful tissue-specific account in ISCU myopathy. It also makes the CANOMAD respiratory deterioration urgent, where the retained MontMedical section leaves the priority buried. Those advantages are reflected in the ratings.

What MontMedical needs to keep improving

Put urgent implications where readers can see them, make the next diagnostic step explicit, and replace dense result lists with a short explanation of the mechanism. Precision should make the answer easier to act on, rather than merely longer.

Why favour MontMedical's approach? Its clearest advantage here is disciplined interpretation: explain what the experiment establishes, retain the strong leading diagnosis and identify the test that would resolve the remaining causal link. The selected historical ratings show that advantage on particular questions; they do not establish universal superiority or clinical efficacy.